EveryWare Global Inc.
EveryWare Global Amends Credit Agreements; Announces Equity Investment by Monomoy
LANCASTER, Ohio, July 30, 2014 (GLOBE NEWSWIRE) -- EveryWare Global, Inc. ("EveryWare" or the "Company") (Nasdaq:EVRY), announced today it amended its Term Loan Agreement and ABL Facility. The Company also announced that it entered into a Securities Purchase Agreement with Monomoy Capital Partners ("Monomoy"), whereby Monomoy agreed to invest $20 million in return for EveryWare's Series A Senior Redeemable Preferred Stock with a liquidation preference of $21.2 million and warrants to purchase 4,438,005 shares of the Company's common stock.
Mines Management Inc.
Mines Management Closes Unit Offering
SPOKANE, Wash., July 30, 2014 (GLOBE NEWSWIRE) -- Mines Management, Inc. ("Mines Management" or the "Company") (NYSE-MKT:MGN) (TSX:MGT) is pleased to announce that it has closed the previously announced financing in which it had agreed to sell 4,000 units consisting of one share of the Company's Series B 6% Convertible Preferred Stock, no par value, and a warrant to purchase approximately 636 shares of the Company's common stock, par value $0.001 per share, at a price to the public of $1,000 per unit. Each share of Series B Convertible Preferred Stock is convertible into shares of common stock at a conversion rate of approximately 1,271 shares of common stock for each share of Series B Convertible Preferred Stock (equivalent to a conversion price of $0.7866 per share of common stock). The warrants are immediately exercisable at an exercise price of $1.0816 per share and will expire 52 months from the date of issuance. The offering yielded gross proceeds, before estimated offering expenses, of $4.0 million, and Mines Management intends to use the net proceeds from this offering for (i) the advancement of the permitting process for its Montanore Project and preparation for the delineation drilling program, which will include completion of the dewatering and rehabilitation of the Libby adit and (ii) general corporate purposes, including possible acquisition and exploration of new mining properties.
Bio Blast Pharma
Bio Blast Pharma Prices Initial Public Offering of $35,200,000 of Ordinary Shares
TEL AVIV, Israel, July 30, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. ("BioBlast"), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today the pricing of its initial public offering of 3,200,000 ordinary shares at an initial public offering price of $11.00 per share. The gross proceeds to BioBlast from the initial public offering are expected to be $35,200,000, before underwriting discounts and commissions and other estimated offering expenses. BioBlast has granted the underwriters a 30-day option to purchase up to 480,000 additional ordinary shares to cover over-allotments, if any, at the public offering price less the underwriting discount. The ordinary shares have been approved for listing on The NASDAQ Global Market under the ticker symbol "ORPN" and are expected to begin trading on July 31, 2014. The offering is expected to close on August 5, 2014, subject to customary closing conditions.
EDAP TMS SA
EDAP Updates on FDA Advisory Committee Meeting on Ablatherm-HIFU for the Treatment of Prostate Cancer
LYON, France, July 30, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration's (FDA) Gastroenterology and Urology Devices Panel (GUDP) voted 3 yes, 5 no with 1 abstention on the question of safety, 9 no on the question of efficacy, and 8 no with 1 abstention for the risk/benefit ratio for the use of its Ablatherm-HIFU device for the treatment of low-risk, localized prostate cancer.
Innocoll AG Announces Closing of Initial Public Offering
ATHLONE, Ireland, July 30, 2014 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced the closing of its public offering of 6,500,000 American Depositary Shares ("ADSs"), each representing 1/13.25 ordinary shares, at a public offering price of $9.00 per ADS. As part of the public offering, Sofinnova Venture Partners VIII, L.P., or Sofinnova, purchased an aggregate of 1,666,667 ADSs at the public offering price. Sofinnova will have a right to nominate one member to the Company's supervisory board. All of the ADSs were offered by the Company. The Company's ADSs are listed on The NASDAQ Global Market under the symbol "INNL." In addition, the Company has granted the underwriters an option until August 23, 2014 to purchase up to an additional 975,000 ADSs at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.